Provectus Biopharmaceutica-APVCT
13F holders, Q3 2025 (September 30)7holders
0new positions
0sold out
$0.09avg. 13F price*
At the end of Q3 2025, 7 institutions reported holding Provectus Biopharmaceutica-A (PVCT) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Home Federal Bank of Tennessee ($9K), Wealth Preservation Advisors, LLC ($5K) and Atlas Wealth LLC ($2K).
- Company
- Provectus Biopharmaceutica-A
- CUSIP
- 74373P108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 600 shares bought, net +600 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Home Federal Bank of Tennessee | 0.00% | No change | 100,000 | $9K |
| Wealth Preservation Advisors, LLC | 0.00% | Add +1.1% | 52,600 | $5K |
| Atlas Wealth LLC | 0.00% | No change | 26,620 | $2K |
| Academy Capital Management | 0.00% | No change | 20,000 | $2K |
| LBMC Investment Advisors, LLC | 0.00% | No change | 20,000 | $2K |
| Financial Symmetry Inc | 0.00% | No change | 10,191 | $907 |
| Huntington National Bank | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PVCT's weight in each manager's 13F, not the share of Provectus Biopharmaceutica-A the manager owns.